The present invention relates generally to implantable medical devices, and specifically to delivery tools and implantable medical devices comprising a shape memory material.
Some materials, both organic and metallic, have shape memory. An article made of such materials when deformed “remembers” its original, cold-forged shape, and returns to its pre-deformed shape when heated. The three main shape memory alloys are copper-zinc-aluminum-nickel, copper-aluminum-nickel, and nickel-titanium (NiTi). NiTi shape memory alloys have two different temperature-dependent crystal structures (phases) called “martensite” (lower temperature) and austenite (higher temperature or parent phase). Several properties of austenite NiTi and martensite NiTi are notably different.
When heated, martensite NiTi begins to transform into austenite at a temperature called the austenite start temperature (As), and completes the transformation at a temperature called the austenite finish temperature (Af). When cooled, austenite NiTi begins to transform into martensite at a temperature that is called the martensite start temperature (Ms), and is again completely reverted at a temperature called the martensite finish temperature (Mf).
Composition and metallurgical treatments have dramatic impacts on the above-mentioned transition temperatures. For practical applications, NiTi can have three different forms: martensite, stress-induced martensite (superelastic), and austenite. When the material is in its martensite form, it is soft and ductile and can be easily deformed (somewhat like soft pewter). Superelastic NiTi is highly elastic (rubber-like), while austenitic NiTi is quite strong and hard (similar to titanium).
NiTi has all of these properties, and their specific expression depends on the temperature in which the NiTi is used.
The temperature range for the martensite-to-austenite transformation, i.e., soft-to-hard transition, that takes place upon heating is somewhat higher than that for the reverse transformation upon cooling. The difference between the transition temperatures upon heating and cooling is called hysteresis (denoted as H). Hysteresis is generally defined as the difference between the temperatures at which the material is 50% transformed to austenite upon heating and 50% transformed to martensite upon cooling. This difference can be up to 20-30 degrees C. In practice, this means that an alloy designed to be completely transformed by body temperature upon heating (Af<37 degrees C.) would require cooling to about +5 degrees C. to fully retransform into martensite (Mf).
One of the commercial uses of shape memory alloy exploits the pseudo-elastic properties of the metal during the high-temperature (austenitic) phase. This is the result of pseudoelasticity; the martensitic phase is generated by stressing the metal in the austenitic state and this martensite phase is capable of large strains. With the removal of the load, the martensite transforms back into the austenite phase and resumes its original shape. This allows the metal to be bent, twisted and pulled, before reforming its shape when released. This means the frames of shape memory alloy glasses are claimed to be “nearly indestructible” because it appears no amount of bending results in permanent plastic deformation.
The martensite temperature of shape memory alloys is dependent on a number of factors including alloy chemistry. Shape memory alloys with transformation temperatures in the range of 60-1450 K have been made.
Many shape memory alloys (SMAs) are known to display stress-induced martensite (SIM). When an SMA sample exhibiting stress-induced martensite is stressed at a temperature above Ms (so that the austenitic state is initially stable), but below Md (the maximum temperature at which martensite formation can occur even under stress) it first deforms elastically and then, at a critical stress, begins to transform by the formation of stress-induced martensite. Depending on whether the temperature is above or below As, the behavior when the deforming stress is released differs. If the temperature is below As, the stress-induced martensite is stable; but if the temperature is above As, the martensite is unstable and transforms back to austenite, with the sample returning (or attempting to return) to its original shape. The effect is seen in almost all alloys which exhibit a thermoelastic martensitic transformation, along with the shape memory effect. However, the extent of the temperature range over which SIM is seen and the stress and strain ranges for the effect vary greatly with the alloy.
Ryhänen J, in “Biocompatibility evaluation of nickel-titanium shape memory metal alloy,” Academic Dissertation, Faculty of Medicine, Department of Surgery, University of Oulu, Finland (May 1999), which is incorporated herein by reference, describes the shape memory effect, superelasticity, and good damping properties that make the nickel-titanium shape memory metal alloy (Nitinol or NiTi) a fascinating material for surgical applications. Among other things, the dissertation describes the mechanical properties of NiTi in Section 2.3.8, including Table I thereof.
Some applications of the present invention provide medical apparatus comprising a hollow placement device and a stent body restrained therein. The placement device comprises a restraining member, which is configured to rotatively release the stent body therefrom. Unlike in some conventional techniques for deploying a stent body, in some applications of the present invention an outer tube need not be axially withdrawn in order to release the stent body. Therefore, in some applications of the present invention a proximal stopper is not needed to prevent the stent body from being withdrawn proximally as the outer tube is withdrawn. The stent body thus is less likely to fold or otherwise become distorted during deployment.
The medical apparatus comprises structural stent elements, at least a portion of which define the stent body. The stent body is configured to assume radially-compressed and radially-expanded states. For some applications, the medical apparatus further comprises an implantable-grade fabric securely attached to and at least partially covering the stent body.
At least a portion of stent body is initially disposed, while in the radially-compressed state, in the restraining member. The restraining member is configured to assume at least (a) a first rotational state, in which the restraining member restrains the at least a portion of the stent body in the radially-compressed state, and (b) a second rotational state, in which the restraining member releases the at least a portion of the stent body, thereby allowing the at least a portion of the stent body to transition to the radially-expanded state.
For some applications, the restraining member comprises at least two generally arcuate sections, which together define at least a circumferential portion of a generally tubular structure. The restraining member is configured such that (a) when the restraining member is in the first rotational state, the arcuate sections are rotationally disposed with respect to each other around a central longitudinal axis of the restraining member so as to restrain the at least a portion of the stent body in the radially-compressed state; and (b) when the restraining member is in the second rotational state, the arcuate sections are rotationally disposed with respect to each other around the axis so as to not restrain the stent body within the restraining member, thereby releasing the stent body from the restraining member and allowing the at least a portion of the stent body to transition to the radially-expanded state.
Some applications of the present invention provide another medical apparatus comprising structural stent elements, at least a portion of which are shaped so as to define (a) one or more generally circumferential bands, and (b) a plurality of engagement members that are joined to and extend radially inwardly from each of the bands. For some applications, the structural stent elements, including the at least a portion that defines the one or more bands, are shaped so as to define a generally tubular structure. For some applications, the medical apparatus further comprises an implantable-grade fabric securely attached to and at least partially covering the generally tubular structure.
The medical apparatus further comprises an elongated latch member which is threaded through the engagement members, thereby physically latching engagement members. Typically, the elongated latch member comprises a wire or a hollow tube. The engagement members and each of the one or more bands are configured such that (a) when the latch member is threaded through and thus physically latching the engagement members, the engagement members retain the band in a radially-compressed state; and (b) when the latch member is removed from the engagement members, the band assumes a radially-expanded state.
For some applications, the engagement members have (a) respective first ends, which are joined to and extend from one of one or more bands, (b) respective second ends, which are joined to and extend from the band at respective junctions, and (c) respective curved portions between the respective first and the respective second ends. When the latch member is threaded through the engagement members, the curved portions pass around the latch member. As a result, the latch member holds the curved portions near a central longitudinal axis of the band. The engagement members thus prevent the band from expanding radially.
For some of the applications described above, the structural stent elements comprise a shape memory alloy. For example, the shape memory alloy may comprise a nickel and titanium, and, optionally, additionally cobalt. The shape memory element may comprise any shape memory alloy known in the art that is characterized by a stress-induced martensitic state and an unstressed austenitic state. For some applications, suitable alloys are those that display stress-induced martensite at temperatures near mammalian (e.g., human) body temperature (35-40 degrees C.).
There is therefore provided, in accordance with an application of the present invention, medical apparatus for insertion into a mammalian body, the apparatus including:
structural stent elements, at least a portion of which are shaped so as to define:
an elongated latch member which is threaded through the engagement members, thereby physically latching the engagement members,
wherein the band and the engagement members are configured such that:
For some applications, the elongated latch member includes an element selected from the group consisting of: a wire and a hollow tube.
For some applications, the engagement members have (a) respective first ends, which are joined to and extend from the band, (b) respective second ends, which are joined to and extend from the band at respective junctions, and (c) respective curved portions between the respective first and the respective second ends. For some applications, the circumferential band has distal and proximal ends, and all of the engagement members are shaped such that the curved portions are disposed more proximally than the junctions, when the latch member physically latches the engagement members. Alternatively, for some applications, the circumferential band has distal and proximal ends, and wherein, when the latch member physically latches the engagement members: a first subset of the engagement members are shaped such that the curved portions thereof are disposed more distally than the junctions thereof, a second subset of the engagement members are shaped such that the curved portions thereof are disposed more proximally than the junctions thereof, and the first and the second subsets do not include any common engagement members.
For any of the applications described above, the at least a portion of the structural stent elements may be shaped so as to define a plurality of generally circumferential bands, and respective subsets of the engagement members are joined to and extend radially inwardly from the bands.
For any of the applications described above, at least a portion of the structural stent elements of the band may be arranged as a plurality of pairs of two respective generally straight, adjacently disposed structural stent elements joined by respective peaks, and each of the engagement members may have (a) a first end, which is joined to and extends from one of the generally straight structural stent elements of one of the pairs, (b) a second end, which is joined to and extends from the other of the generally straight structural stent elements of the one of the pairs, and (c) a curved portion between the first and the second ends of the engagement member. For some applications, the latch member, when physically latching the engagement members, rests against an inner surface of the curved portion.
For any of the applications described above, the structural stent elements, including the at least a portion that defines the at least one band, may be shaped so as to define a generally tubular structure, and the medical apparatus further includes an implantable-grade fabric securely attached to and at least partially covering the generally tubular structure.
For any of the applications described above, the apparatus may further include a hollow, elongated delivery shaft, in which the at least one band is initially positioned, with the latch member threaded through the engagement members. For some applications, the delivery shaft and the at least one band are configured such that the at least one band, when retained by the latch member in the radially-compressed state, is slidably positioned in the delivery shaft. Alternatively, for some applications, the radially-compressed state is a first radially-compressed state, and the delivery shaft and the at least one band are configured such that the delivery shaft holds the at least one band in a second radially-compressed state that is more radially compressed than the first radially-compressed state.
For any of the applications described above, the structural stent elements may include a shape memory alloy. For some applications, the shape memory alloy includes nickel and titanium, and, optionally, further includes cobalt.
For some applications, (a) the shape memory alloy includes a pseudoelastic shape-memory alloy, the alloy displaying reversible stress-induced martensite at between 35 and 40 degrees C. such that it has a stress-induced martensitic state and an austenitic state; (b) when the alloy is in the stress-induced martensitic state, the band has a deformed shape that provides the radially-compressed state; and (c) when the alloy is in the austenitic state, the band has a different unstressed shape that provides the radially-expanded state.
For some applications, the band and the engagement members are configured such that:
when the latch member physically latches the engagement members and the shape memory alloy is at a temperature greater than an austenite start temperature of the shape memory alloy, the latch member retains the shape memory alloy of the band so that at least a portion of the alloy is in at least a partially stress-induced martensitic state and the band is in the deformed shape, and
when the latch member is removed from the plurality of engagement members and the shape memory alloy is at a temperature greater than the austenite start temperature, at least a portion of the shape memory alloy at least partially transitions to an austenitic state from the stress-induced martensitic state, thereby causing a transformation of the band from the deformed shape to the unstressed shape.
For some applications, the shape memory alloy is realized such that the transformation occurs without any change in temperature of the latch member or the shape memory alloy. Alternatively, for some applications, the shape memory alloy is realized such that the transformation occurs with a change in temperature of at least one element selected from group consisting of: the latch member and the shape memory alloy.
For some applications, the latch member is configured to function as a heat dissipation element, which is in physical contact with the shape memory alloy at least when the latch member physically latches the engagement members. For some applications, the latch member, when physically latching the engagement members, is disposed adjacent to at least a portion of the shape memory alloy. For some applications, the latch member, when physically latching the engagement members, is in direct physical contact with at least a portion of the shape memory alloy.
For some applications, the apparatus further includes a heat dissipation element, which is in thermal contact with the shape memory alloy at least when the band is in the radially-compressed state. For some applications, the apparatus further includes a hollow, elongated delivery shaft, in which the at least one band is initially positioned, retained by the latch member in the radially-compressed state, and the elongated delivery shaft includes the heat dissipation element.
For some applications, the heat dissipation element is disposed adjacent to at least part of the shape memory alloy while the shape memory alloy is in the stress-induced martensitic state.
For some applications, the heat dissipation element includes a plurality of heat dissipation elements.
For some applications, the heat dissipation element is adapted to lose thermal energy at a rate faster than the rate of change of thermal energy caused by the change in temperature.
There is further provided, in accordance with an application of the present invention, a method including:
providing (a) structural stent elements, at least a portion of which are shaped so as to define (i) at least one generally circumferential band, and (ii) a plurality of engagement members that are joined to and extend radially inwardly from the band, and (b) an elongated latch member which is threaded through the engagement members, thereby physically latching the engagement members;
transvascularly introducing the at least one band into a blood vessel of a mammalian subject while the latch member is threaded through and thus physically latches the engagement members, such that the engagement members retain the band in a radially-compressed state; and
thereafter, removing the latch member from the engagement members, thereby transitioning the band to a radially-expanded state.
For some applications, providing the latch member includes providing a latch member that includes an element selected from the group consisting of: a wire and a hollow tube.
For some applications, providing the engagement members includes providing engagement members that have (a) respective first ends, which are joined to and extend from the band, (b) respective second ends, which are joined to and extend from the band at respective junctions, and (c) respective curved portions between the respective first and the respective second ends.
For some applications, the structural stent elements, including the at least a portion that defines the at least one band, are shaped so as to define a generally tubular structure, and further including providing an implantable-grade fabric securely attached to and at least partially covering the generally tubular structure.
For some applications, transvascularly introducing includes transvascularly introducing the at least one band while the at least one band is positioned in a hollow, elongated delivery shaft, with the latch member threaded through the engagement members.
For some applications, transvascularly introducing includes advancing the delivery shaft to a target site in the blood vessel, and thereafter sliding the at least one band through at least a portion of the delivery shaft while the at least one band is retained by the latch member in the radially-compressed state.
For some applications, the radially-compressed state is a first radially-compressed state, and transvascularly introducing includes:
transvascularly introducing delivery shaft while the delivery shaft holds the at least one band in a second radially-compressed state that is more radially compressed than the first radially-compressed state; and
thereafter, withdrawing the delivery shaft so as to release the at least one band from the delivery shaft, thereby causing the at least one band to radially expand to the first radially-compressed state.
For some applications, providing the structural stent elements includes providing structural stent elements that include a shape memory alloy.
There is still further provided, in accordance with an application of the present invention, medical apparatus for insertion into a mammalian body, the apparatus including:
structural stent elements, at least a portion of which define a stent body that is configured to assume radially-compressed and radially-expanded states; and
a restraining member, in which at least a portion of the stent body is disposed in the radially-compressed state, and which restraining member is configured to assume at least:
For some applications, the restraining member includes at least two generally arcuate sections, which together define at least a circumferential portion of a generally tubular structure, and wherein:
when the restraining member is in the first rotational state, the arcuate sections are rotationally disposed with respect to each other around a central longitudinal axis of the restraining member so as to restrain the at least a portion of the stent body in the radially-compressed state, and
when the restraining member is in the second rotational state, the arcuate sections are rotationally disposed with respect to each other around the axis so as to not restrain the stent body within the restraining member, thereby releasing the stent body from the restraining member and allowing the at least a portion of the stent body to transition to the radially-expanded state.
For some applications, when the restraining member is in the first rotational state, circumferentially-adjacent ones of the arcuate sections partially circumferentially overlap one another along at least portions of respective axial lengths of the arcuate sections. For some applications, when the restraining member is in the first rotational state, the circumferentially-adjacent ones of the arcuate sections circumferentially overlap one another along less than respective entire axial lengths of portions of the arcuate sections that restrain the at least a portion of the stent body.
For some applications, when the restraining member is in the second rotational state, the arcuate sections circumferentially overlap one another to a greater extent than when in the first rotational state. For some applications, when the restraining member is in the first rotational state, the arcuate sections do not circumferentially overlap one another.
For some applications, when the restraining member is in the first rotational state, a greatest arc between circumferentially-adjacent ones of the arcuate sections, along respective entire axial lengths of portions of the arcuate sections that restrain the at least a portion of the stent body, is no more than 150 degrees. For some applications, when the restraining member is in the first rotational state, the greatest arc between circumferentially-adjacent ones of the arcuate sections is no more than 120 degrees.
For some applications, the restraining member includes exactly three generally arcuate sections. For some applications, the restraining member includes between two and six generally arcuate sections.
For some applications, when the restraining member is in the first rotational state, the arcuate sections collectively circumscribe one or more arcs having an angular sum of at least 220 degrees. For some applications, the angular sum equals 360 degrees.
For some applications, when the restraining member is in the second rotational state, the arcuate sections collectively circumscribe one or more arcs having an angular sum of no more than 150 degrees, such as no more than 90 degrees.
For some applications, the arcuate sections are shaped so as to define (a) respective longitudinal base strips, and (b) respective pluralities of circumferential tabs that extend circumferentially from the respective longitudinal base strips, and wherein, when the restraining member is in the first rotational state, the longitudinal base strips of circumferentially-adjacent ones of the arcuate sections do not circumferentially overlap one another, and the circumferential tabs overlap the longitudinal base strips of circumferentially-adjacent ones of the arcuate sections. For some applications, when the restraining member is the second rotational state, the longitudinal base strips of at least some of the arcuate sections at least partially overlap one another. For some applications, when the restraining member is the second rotational state, the longitudinal base strips of all of the arcuate sections at least partially overlap one another.
For some applications, portions of the arcuate sections that restrain the at least a portion of the stent body in the radially-compressed state have respective lengths along the axis, and an average of the lengths is at least 30% of an average length of the at least a portion of the stent body when in the radially-compressed state.
For any of the applications described above, a portion of the restraining element that restrains the at least a portion of stent body 20 in the radially-compressed state may have a length along the axis of at least 30% of an average length of the at least a portion of the stent body when in the radially-compressed state.
For any of the applications described above, the apparatus may further include an implantable-grade fabric securely attached to and at least partially covering the stent body.
For any of the applications described above, the structural stent elements may include a shape memory alloy. For some applications, the shape memory alloy includes nickel and titanium, and, optionally further includes cobalt.
For some applications, (a) the shape memory alloy includes a pseudoelastic shape-memory alloy, the alloy displaying reversible stress-induced martensite at between 35 and 40 degrees C. such that it has a stress-induced martensitic state and an austenitic state, (b) when the alloy is in the stress-induced martensitic state, the stent body has a deformed shape that provides the radially-compressed state, and (c) when the alloy is in the austenitic state, the stent body has a different unstressed shape that provides the radially-expanded state. For some applications, when the restraining member is in the first rotational state and the shape memory alloy is at a temperature greater than an austenite start temperature of the shape memory alloy, the restraining member confines and stresses the memory alloy element so that the at least a portion of the stent body is retained in a stress-induced martensite state. For some applications, when the at least a portion of the stent body is released and transitions to the radially-expanded state, the transformation of the stent body occurs with a change in the temperature of at least one element from the group consisting of: the restraining member, the structural stent elements including the shape memory alloy, and the mammalian body. For some applications, the apparatus further includes a heat dissipation element in thermal contact with at least one element selected from the group consisting of: the restraining member and the structural stent elements.
There is additionally provided, in accordance with an application of the present invention, a method including:
providing (a) structural stent elements, at least a portion of which define a stent body that is configured to assume radially-compressed and radially-expanded states, and (b) a restraining member, in which at least a portion of the stent body is disposed in the radially-compressed state;
transvascularly introducing the stent body into a blood vessel of a mammalian subject while the restraining member is in a first rotational state, in which the restraining member restrains the at least a portion of the stent body in the radially-compressed state; and
thereafter, causing the restraining member to assume a second rotational state, so that the restraining member releases the at least a portion of the stent body, thereby allowing the at least a portion of the stent body to transition to the radially-expanded state.
For some applications, providing the restraining member includes providing a restraining member that includes at least two generally arcuate sections, which together define at least a circumferential portion of a generally tubular structure, and (a) when the restraining member is in the first rotational state, the arcuate sections are rotationally disposed with respect to each other around a central longitudinal axis of the restraining member so as to restrain the at least a portion of the stent body in the radially-compressed state, and (b) when the restraining member is in the second rotational state, the arcuate sections are rotationally disposed with respect to each other around the axis so as to not restrain the stent body within the restraining member, thereby releasing the stent body from the restraining member and allowing the at least a portion of the stent body to transition to the radially-expanded state.
For some applications, when the restraining member is in the first rotational state, circumferentially-adjacent ones of the arcuate sections partially circumferentially overlap one another along at least portions of respective axial lengths of the arcuate sections. For some applications, when the restraining member is in the first rotational state, the circumferentially-adjacent ones of the arcuate sections circumferentially overlap one another along less than respective entire axial lengths of portions of the arcuate sections that restrain the at least a portion of the stent body.
For some applications, when the restraining member is in the second rotational state, the arcuate sections circumferentially overlap one another to a greater extent than when in the first rotational state. For some applications, when the restraining member is in the first rotational state, the arcuate sections do not circumferentially overlap one another.
For some applications, the method further includes providing an implantable-grade fabric securely attached to and at least partially covering the stent body.
For some applications, providing the structural stent elements includes providing structural stent elements that include a shape memory alloy.
The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:
As shown in
Also as shown in
Restraining member 30 is configured to assume at least:
Restraining member 30 typically can assume many additional rotational states, some of which restrain the stent body, some of which do not, and, optionally, some of which partially restrain the stent body. By way of example, restraining member 30 is shown in one first rotational state in
For some applications, restraining member 30 comprises at least two generally arcuate sections 34, which together define at least a circumferential portion of a generally tubular structure 36. Typically, restraining member 30 comprises between two and six generally arcuate sections 34, such as exactly three generally arcuate sections 34A, 34B, and 34C, as shown. Restraining member 30 is configured such that:
As used in the present application, including in the claims, “tubular” means having the form of an elongated hollow object that defines a conduit therethrough. A “tubular” structure may have varied cross-sections therealong, and the cross-sections are not necessarily circular. For example, one or more of the cross-sections may be generally circular, or generally elliptical but not circular, or circular.
Reference is additionally made to
For some applications, when restraining member 30 is in the first rotational state, circumferentially-adjacent ones of arcuate sections 34 partially circumferentially overlap one another along at least portions of respective axial lengths of the arcuate sections, such as shown in
Alternatively, for other applications, when restraining member 30 is in the first rotational state, arcuate sections 34 do not circumferentially overlap one another (configuration not shown); in this configuration, the arcuate sections are nevertheless distributed around axis 40 so as to restrain the at least a portion of stent body 20 in the radially-compressed state. For these latter applications, when restraining member 30 is in the first rotational state, a greatest arc between circumferentially-adjacent ones of the arcuate sections, along respective entire axial lengths of portions of the arcuate sections that restrain the at least a portion of the stent body (i.e., between the most circumferentially extreme portions of each arcuate section, at which circumferential locations no portion of any arcuate section is disposed), is no more than 150 degrees, such as no more than 120 degrees, in order to restrain the at least a portion of stent body 20 in the radially-compressed state.
For some applications, when restraining member 30 is in the second rotational state, such as shown in
For some applications, when restraining member 30 is in the first rotational state, arcuate sections 34 collectively circumscribe (i.e., without double-counting the arcs of any circumferentially-overlapping portions) a complete circle, i.e., exactly one 360-degree arc, as shown in
For some applications, when restraining member 30 is in the second rotational state, such as shown in
Reference is still made to
Typically, longitudinal base strips 42 extend along an entire axial length of their respective arcuate sections 34, as shown in
For some applications, when restraining member 30 is the second rotational state, longitudinal base strips 42 of at least some of (e.g., all of) arcuate sections 34 at least partially overlap one another.
For some applications, portions of arcuate sections 34 that restrain the at least a portion of stent body 20 in the radially-compressed state have respective lengths along the axis 40, and an average of the lengths is at least 30% of an average length of the at least a portion of stent body 20 when in the radially-compressed state. For some applications, a portion of restraining element 30 that restrains the at least a portion of stent body 20 in the radially-compressed state has a length along the axis of at least 30% of an average length of the at least a portion of stent body 20 when in the radially-compressed state.
For some applications, structural stent elements 32 comprise a shape memory alloy. For example, the shape memory alloy may comprise a nickel and titanium, and, optionally, additionally cobalt. The shape memory element may comprise any shape memory alloy known in the art that is characterized by a stress-induced martensitic state and an unstressed austenitic state. For some applications, suitable alloys are those that display stress-induced martensite at temperatures near mammalian (e.g., human) body temperature (35-40 degrees C.). For example, one such alloy is the nickel/titanium/vanadium alloy described in U.S. Pat. No. 4,505,767 to Quin, which is incorporated herein by reference. The shape memory alloy is typically configured such that stent body 20 is self-expanding when not radially restrained.
For some applications, the shape memory alloy comprises a pseudoelastic shape-memory alloy, the alloy displaying reversible stress-induced martensite at between 35 and 40 degrees C. such that it has a stress-induced martensitic state and an austenitic state. When the alloy is in the stress-induced martensitic state, stent body 20 has a deformed shape that provides the radially-compressed state. When the alloy is in the austenitic state, the stent body has a different unstressed shape that provides the radially-expanded state.
For some applications, when restraining member 30 is in the first rotational state and the shape memory alloy is at a temperature greater than an austenite start temperature of the shape memory alloy, restraining member 30 confines and stresses the memory alloy element so that the at least a portion of stent body 20 is retained in a stress-induced martensite state.
For some applications, when the at least a portion of stent body 20 is released and transitions to the radially-expanded state, the transformation of stent body 20 occurs with a change in the temperature of at least one element from the group consisting of: restraining member 30 (typically, arcuate sections 34 thereof), structural stent elements 32 comprising the shape memory alloy, and the mammalian body.
For some applications, medical apparatus 10 further comprises a heat dissipation element in thermal contact with at least one element selected from the group consisting of: restraining member 30 and structural stent elements 32. The heat dissipation element dissipates at least a portion of any heat that may be released by the stent body as it radially expands.
Reference is made again to
The rotational state of restraining member 30 is typically controlled using a handle located external to the patient's body. Typically, the surgeon manually actuates (e.g., by rotating a handle, pressing on a knob, advancing a lever, etc.) one or more knobs that transmit the rotation to the arcuate sections, such as via one or more wires, shafts, and/or another gearing mechanism. Alternatively, the handle comprises one or more motors that are actuated to rotate the arcuate sections.
Reference is now made to
For some applications, structural stent elements 110, including the at least a portion that defines the one or more bands 112, are shaped so as to define a generally tubular structure. For some applications, as shown in
Medical apparatus 100 further comprises an elongated latch member 118 which is threaded through engagement members 114, thereby physically latching engagement members 114. Typically, elongated latch member 118 comprises a wire (typically comprising a metal, such as a metal alloy, e.g., any of the alloys described herein) or a hollow tube (which may comprise a metal, such as a metal alloy, e.g., any of the alloys described herein, or plastic).
Engagement members 114 and each of one or more bands 112 are configured such that:
Reference is still made to
For some applications, each of the one or more bands 118 has distal and proximal ends 140 and 142. All of engagement members 114 of a given circumferential band are shaped such that curved portions 136 thereof are disposed more proximally than junctions 134, when latch member 118 physically latches the engagement members. In other words, all of these curved portions generally extend in the same, proximal direction.
For some applications, at least a portion of the structural stent elements of each of one or more bands 112 are arranged as a plurality of pairs 150 of two respective generally straight, adjacently disposed structural stent elements 152A and 152B joined by respective peaks 154.
First end 130 of each of engagement members 114 is joined to and extends from one of the generally straight structural stent elements 152A of one of pairs 150. Second end 132 of the engagement member is joined to and extends from the other 152B of the generally straight structural stent elements of the one of pairs 150. Typically, latch member 118, when physically latching engagement members 114, rests against an inner surface of curved portion 136 of each of engagement member 114. Optionally, circumferentially-adjacent pairs 150 are connected by secondary peaks 156 at an end of the band opposite to the end at which peaks 154 are disposed.
For some applications, as shown in
Alternatively, for some applications, delivery shaft 160 and one or more bands 112 are configured such that the shaft snugly (non-slidably) holds the bands in a second radially-compressed state that is more radially compressed than the radially-compressed state in which latch member 118 restrains the bands. Proximal withdrawal of the delivery shaft with respect to the bands releases the bands to a partial deployment state, in which the bands are in the radially-compressed state in which latch member 118 restrains the bands. When the latch member is removed from the engagement members, the bands assume the radially-expanded state, thereby completing deployment. This two-stage deployment approach may be useful in cases where deployment accuracy—axial and/or orientational—is of high importance, such as when deploying a main stent-graft module that has side-branch fenestrations, which fenestrations should be positioned as accurately as possible relative to the anatomical side branches.
For some applications, structural stent elements 110 comprise a shape memory alloy. For example, the shape memory alloy may comprise a nickel and titanium, and, optionally, additionally cobalt. The shape memory element may comprise any shape memory alloy known in the art that is characterized by a stress-induced martensitic state and an unstressed austenitic state. For some applications, suitable alloys are those that display stress-induced martensite at temperatures near mammalian (e.g., human) body temperature (35-40 degrees C.). For example, one such alloy is the nickel/titanium/vanadium alloy described in U.S. Pat. No. 4,505,767 to Quin, which is incorporated herein by reference. The shape memory alloy is typically configured such that bands 112 are self-expanding when not radially restrained.
For some applications, the shape memory alloy comprises a pseudoelastic shape-memory alloy, the alloy displaying reversible stress-induced martensite at between 35 and 40 degrees C. such that it has a stress-induced martensitic state and an austenitic state. When the alloy is in the stress-induced martensitic state, each of one or more bands 112 has a deformed shape that provides the radially-compressed state. When the alloy is in the austenitic state, each of the bands has a different unstressed shape that provides the radially-expanded state.
For some applications, one or more bands 112 and engagement members 114 are configured such that:
For some applications, the shape memory alloy is realized such that the transformation occurs without any change in temperature of the latch member or the shape memory alloy. Alternatively, the shape memory alloy is realized such that the transformation occurs with a change in temperature of at least one element selected from group consisting of: the latch member and the shape memory alloy.
For some applications, latch member 118 is configured to function as a heat dissipation element, which is in physical contact with the shape memory alloy at least when the latch member physically latches engagement members 114. For some applications, latch member 118, when physically latching engagement members 114, is disposed adjacent to at least a portion of the shape memory alloy. Alternatively or additionally, for some applications, latch member 118, when physically latching engagement members 114, is in direct physical contact with at least a portion of the shape memory alloy. The latch member, functioning as the heat dissipation element, dissipates at least a portion of any heat that may be released by bands 112 as they radially expand.
For some applications, latch member 118 is configured to function as a heat application element, which is in thermal contact with the shape memory alloy at least when the latch member physically latches engagement members 114. For some applications, latch member 118, when physically latching engagement members 114, is disposed adjacent to at least a portion of the shape memory alloy. Alternatively or additionally, for some applications, latch member 118, when physically latching engagement members 114, is in direct physical contact with at least a portion of the shape memory alloy. The latch member, functioning as the heat application element, applies at least a portion of any heat that may be absorbed by bands 112 as they radially expand.
For some applications, medical apparatus 100 further comprises a heat dissipation element, which is in thermal contact with the shape memory alloy at least when one or more bands 112 are in the radially-compressed state. For some applications in which elongated delivery shaft 160 is provided, the elongated delivery shaft comprises the heat dissipation element. The heat dissipation element dissipates at least a portion of any heat that may be released by bands 112 as they radially expand.
For some applications, the heat dissipation element is disposed adjacent to at least part of the shape memory alloy while the shape memory alloy is in the stress-induced martensitic state.
For some applications, the heat dissipation element comprises a plurality of heat dissipation elements. For some applications, the heat dissipation element is adapted to lose thermal energy at a rate faster than the rate of change of thermal energy caused by the change in temperature.
For some applications, medical apparatus 100 further comprises a heat application element, which is in thermal contact with the shape memory alloy at least when one or more bands 112 are in the radially-compressed state. For some applications in which elongated delivery shaft 160 is provided, the elongated delivery shaft comprises the heat dissipation element. The heat application element applies at least a portion of any heat that may be absorbed by bands 112 as they radially expand.
For some applications, the heat application element is disposed adjacent to at least part of the shape memory alloy while the shape memory alloy is in the stress-induced martensitic state.
For some applications, the heat application element comprises a plurality of heat application elements.
Reference is made to
Reference is now made to
For some applications, structural stent elements 210, including the at least a portion that defines the one or more bands 212, are shaped so as to define a generally tubular structure. For some applications, as shown in
Medical apparatus 200 further comprises an elongated latch member 218 which is threaded through engagement members 214, thereby physically latching engagement members 214. Typically, elongated latch member 218 comprises a wire or a hollow tube.
Engagement members 214 and each of one or more bands 212 are configured such that:
Reference is still made to
For some applications, each of the one or more bands 218 has distal and proximal ends 240 and 242. A first subset 244 of engagement members 214 are shaped such that curved portions 236 thereof are disposed more distally than junctions 234 thereof, and a second subset 246 of engagement members 214 are shaped such that curved portions 236 thereof are disposed more proximally than junctions 234 thereof. In other words, the curved portions of first subset 244 generally extend in the opposite direction as the curved portions of second subset 246. First and second subsets 244 and 246 do not include any common engagement members 214, i.e., are non-overlapping sets. This configuration may prevent engagement members 214 from giving band 218 a biased shape.
For some applications, structural stent elements 210 comprise a shape memory alloy, such as described regarding structural stent elements 110 hereinabove with reference to
Reference is still made to
Although the techniques described herein have been generally described for implanting a stent-graft in a blood vessel, the techniques maybe used to implant other implantable medical devices that are introduced into the body in a relatively compact state and used within the body in a relatively expanded state. Non-limiting examples of such implantable medical devices include stents, coil stents and filters, catheters, cannulas, intrauterine contraceptive devices (IUDs), bone plates, marrow nails, dental arch wires, filters, bone staples, heart valves, and clips.
The scope of the present invention includes embodiments described in the following applications, which are assigned to the assignee of the present application and are incorporated herein by reference. In an embodiment, techniques and apparatus described in one or more of the following patent applications are combined with techniques and apparatus described herein. In particular, the techniques with reference to
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present patent application claims priority from U.S. Provisional Application 61/438,977, filed Feb. 3, 2011, which is assigned to the assignee of the present application and is incorporated herein by reference.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/IL2012/000060 | 2/2/2012 | WO | 00 | 2/8/2013 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2012/104842 | 8/9/2012 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4355426 | MacGregor | Oct 1982 | A |
4505767 | Quin | Mar 1985 | A |
4562596 | Kornberg | Jan 1986 | A |
4577631 | Kreamer | Mar 1986 | A |
4617932 | Kornberg | Oct 1986 | A |
4665906 | Jervis | May 1987 | A |
4739762 | Palmaz | Apr 1988 | A |
4787899 | Lazarus | Nov 1988 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4938740 | Melbin | Jul 1990 | A |
4969458 | Wiktor | Nov 1990 | A |
5042707 | Taheri | Aug 1991 | A |
5064435 | Porter | Nov 1991 | A |
5104404 | Wolff | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5133732 | Wiktor | Jul 1992 | A |
5192286 | Phan et al. | Mar 1993 | A |
5234448 | Wholey et al. | Aug 1993 | A |
5425739 | Jessen | Jun 1995 | A |
5439446 | Barry | Aug 1995 | A |
5456694 | Marin et al. | Oct 1995 | A |
5486183 | Middleman et al. | Jan 1996 | A |
5507769 | Marin et al. | Apr 1996 | A |
5509923 | Middleman et al. | Apr 1996 | A |
5522880 | Barone et al. | Jun 1996 | A |
5527322 | Klein et al. | Jun 1996 | A |
5549662 | Fordenbacher | Aug 1996 | A |
5554181 | Das | Sep 1996 | A |
5556413 | Lam | Sep 1996 | A |
5562724 | Vorwerk et al. | Oct 1996 | A |
5575818 | Pinchuk | Nov 1996 | A |
5607445 | Summers | Mar 1997 | A |
5613974 | Andreas et al. | Mar 1997 | A |
5632746 | Middleman et al. | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5643340 | Nunokawa | Jul 1997 | A |
5653743 | Martin | Aug 1997 | A |
5676696 | Marcade | Oct 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5693084 | Chuter | Dec 1997 | A |
5728134 | Barak | Mar 1998 | A |
5749879 | Middleman et al. | May 1998 | A |
5755770 | Ravenscroft | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5755774 | Pinchuk | May 1998 | A |
5755777 | Chuter | May 1998 | A |
5755781 | Jayaraman | May 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5782903 | Wiktor | Jul 1998 | A |
5782906 | Marshall et al. | Jul 1998 | A |
5792172 | Fischell et al. | Aug 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5843170 | Ahn | Dec 1998 | A |
5855600 | Alt | Jan 1999 | A |
5860991 | Klein et al. | Jan 1999 | A |
5876432 | Lau et al. | Mar 1999 | A |
5906641 | Thompson et al. | May 1999 | A |
5921994 | Andreas et al. | Jul 1999 | A |
5925076 | Inoue | Jul 1999 | A |
5944750 | Tanner et al. | Aug 1999 | A |
5976178 | Goldsteen et al. | Nov 1999 | A |
5980552 | Pinchasik et al. | Nov 1999 | A |
6015431 | Thornton et al. | Jan 2000 | A |
6016810 | Ravenscroft | Jan 2000 | A |
6030414 | Taheri | Feb 2000 | A |
6033435 | Penn et al. | Mar 2000 | A |
6036725 | Avellanet | Mar 2000 | A |
6059824 | Taheri | May 2000 | A |
6077298 | Tu | Jun 2000 | A |
6099497 | Adams et al. | Aug 2000 | A |
6117145 | Wood et al. | Sep 2000 | A |
6156064 | Chouinard | Dec 2000 | A |
6168615 | Ken | Jan 2001 | B1 |
6200339 | Leschinsky et al. | Mar 2001 | B1 |
6206893 | Klein et al. | Mar 2001 | B1 |
6270524 | Kim | Aug 2001 | B1 |
6283991 | Cox et al. | Sep 2001 | B1 |
6290720 | Khosravi et al. | Sep 2001 | B1 |
6312458 | Golds | Nov 2001 | B1 |
6319287 | Frimberger | Nov 2001 | B1 |
6325823 | Horzewski et al. | Dec 2001 | B1 |
6344056 | Dehdashtian | Feb 2002 | B1 |
6428565 | Wisselink | Aug 2002 | B1 |
6451048 | Berg et al. | Sep 2002 | B1 |
6506211 | Skubitz et al. | Jan 2003 | B1 |
6520988 | Colombo et al. | Feb 2003 | B1 |
6544279 | Hopkins et al. | Apr 2003 | B1 |
6565597 | Fearnot et al. | May 2003 | B1 |
6613075 | Healy et al. | Sep 2003 | B1 |
6613078 | Barone | Sep 2003 | B1 |
6635083 | Cheng et al. | Oct 2003 | B1 |
6648901 | Fleischman et al. | Nov 2003 | B2 |
6652567 | Deaton | Nov 2003 | B1 |
6652571 | White et al. | Nov 2003 | B1 |
6656214 | Fogarty et al. | Dec 2003 | B1 |
6692520 | Gambale et al. | Feb 2004 | B1 |
6695833 | Frantzen | Feb 2004 | B1 |
6695875 | Stelter et al. | Feb 2004 | B2 |
6730117 | Tseng et al. | May 2004 | B1 |
6743195 | Zucker | Jun 2004 | B2 |
6748953 | Sherry et al. | Jun 2004 | B2 |
6752826 | Holloway et al. | Jun 2004 | B2 |
6776794 | Hong et al. | Aug 2004 | B1 |
6808534 | Escano | Oct 2004 | B1 |
6814749 | Cox et al. | Nov 2004 | B2 |
6814752 | Chuter | Nov 2004 | B1 |
6824560 | Pelton | Nov 2004 | B2 |
6846321 | Zucker | Jan 2005 | B2 |
6907285 | Denker et al. | Jun 2005 | B2 |
6908477 | McGuckin, Jr. et al. | Jun 2005 | B2 |
6929660 | Ainsworth et al. | Aug 2005 | B1 |
6942691 | Chuter | Sep 2005 | B1 |
6953469 | Ryan | Oct 2005 | B2 |
6964679 | Marcade et al. | Nov 2005 | B1 |
6986774 | Middleman et al. | Jan 2006 | B2 |
7008441 | Zucker | Mar 2006 | B2 |
7044962 | Elliott | May 2006 | B2 |
7105020 | Greenberg et al. | Sep 2006 | B2 |
7112217 | Kugler et al. | Sep 2006 | B1 |
7115127 | Lindenbaum et al. | Oct 2006 | B2 |
7144421 | Carpenter et al. | Dec 2006 | B2 |
7198638 | Dong | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7223266 | Lindenbaum et al. | May 2007 | B2 |
7261733 | Brown | Aug 2007 | B1 |
7279003 | Berra et al. | Oct 2007 | B2 |
7294145 | Ward | Nov 2007 | B2 |
7306623 | Watson | Dec 2007 | B2 |
7341598 | Davidson et al. | Mar 2008 | B2 |
7393357 | Stelter et al. | Jul 2008 | B2 |
7399313 | Brown | Jul 2008 | B2 |
7407509 | Greenberg et al. | Aug 2008 | B2 |
7413573 | Hartley et al. | Aug 2008 | B2 |
7429269 | Schwammenthal | Sep 2008 | B2 |
7442204 | Schwammenthal | Oct 2008 | B2 |
7473272 | Pryor | Jan 2009 | B2 |
7537609 | Davidson et al. | May 2009 | B2 |
7540881 | Meyer et al. | Jun 2009 | B2 |
7544160 | Gross | Jun 2009 | B2 |
7616997 | Kieval | Nov 2009 | B2 |
7637939 | Tischler | Dec 2009 | B2 |
7662161 | Briganti et al. | Feb 2010 | B2 |
7662168 | McGuckin, Jr. et al. | Feb 2010 | B2 |
7678141 | Greenan et al. | Mar 2010 | B2 |
7722626 | Middleman et al. | May 2010 | B2 |
7731732 | Ken | Jun 2010 | B2 |
7803178 | Whirley et al. | Sep 2010 | B2 |
7815673 | Bloom et al. | Oct 2010 | B2 |
7887575 | Kujawski | Feb 2011 | B2 |
7955373 | Sowinski et al. | Jun 2011 | B2 |
7959662 | Erbel et al. | Jun 2011 | B2 |
7998186 | Hartley | Aug 2011 | B2 |
8016853 | Griffen et al. | Sep 2011 | B2 |
8021419 | Hartley et al. | Sep 2011 | B2 |
8048147 | Adams | Nov 2011 | B2 |
8052741 | Bruszewski et al. | Nov 2011 | B2 |
8066755 | Zacharias et al. | Nov 2011 | B2 |
8080026 | Konstantino | Dec 2011 | B2 |
8080053 | Satasiya et al. | Dec 2011 | B2 |
8133267 | Leonhardt et al. | Mar 2012 | B2 |
8157852 | Bloom et al. | Apr 2012 | B2 |
8167926 | Hartley et al. | May 2012 | B2 |
8172892 | Chuter et al. | May 2012 | B2 |
8172895 | Anderson et al. | May 2012 | B2 |
8226706 | Hartley et al. | Jul 2012 | B2 |
8236040 | Mayberry et al. | Aug 2012 | B2 |
8292951 | Muzslay | Oct 2012 | B2 |
8333800 | Bruszewski et al. | Dec 2012 | B2 |
8337546 | Bruszewski | Dec 2012 | B2 |
8470018 | Hartley et al. | Jun 2013 | B2 |
8491646 | Schreck | Jul 2013 | B2 |
20010000188 | Lenker et al. | Apr 2001 | A1 |
20010004705 | Killion et al. | Jun 2001 | A1 |
20010010006 | Bachinski et al. | Jul 2001 | A1 |
20010014823 | Resseman et al. | Aug 2001 | A1 |
20010034550 | Buirge et al. | Oct 2001 | A1 |
20010044651 | Steinke et al. | Nov 2001 | A1 |
20010044652 | Moore | Nov 2001 | A1 |
20010047198 | Drasler et al. | Nov 2001 | A1 |
20010049550 | Martin et al. | Dec 2001 | A1 |
20010053930 | Kugler et al. | Dec 2001 | A1 |
20020040236 | Lau et al. | Apr 2002 | A1 |
20020099438 | Furst | Jul 2002 | A1 |
20020099441 | Dehdashtian | Jul 2002 | A1 |
20020107564 | Cox et al. | Aug 2002 | A1 |
20020111667 | Girton et al. | Aug 2002 | A1 |
20020123791 | Harrison | Sep 2002 | A1 |
20020156495 | Brenneman et al. | Oct 2002 | A1 |
20020173809 | Fleischman et al. | Nov 2002 | A1 |
20020183783 | Shadduck | Dec 2002 | A1 |
20020193864 | Khosravi et al. | Dec 2002 | A1 |
20030040791 | Oktay | Feb 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030074055 | Haverkost | Apr 2003 | A1 |
20030093145 | Lawrence-Brown et al. | May 2003 | A1 |
20030130720 | DePalma et al. | Jul 2003 | A1 |
20030144725 | Lombardi | Jul 2003 | A1 |
20030153968 | Geis et al. | Aug 2003 | A1 |
20030163187 | Weber | Aug 2003 | A1 |
20030171771 | Anderson et al. | Sep 2003 | A1 |
20030191523 | Hojeibane | Oct 2003 | A1 |
20030199967 | Hartley et al. | Oct 2003 | A1 |
20030199968 | Ainsworth et al. | Oct 2003 | A1 |
20030208192 | Truckai et al. | Nov 2003 | A1 |
20030212449 | Cox | Nov 2003 | A1 |
20030233117 | Adams et al. | Dec 2003 | A1 |
20030236567 | Elliot | Dec 2003 | A1 |
20040015227 | Vardi et al. | Jan 2004 | A1 |
20040015229 | Fulkerson et al. | Jan 2004 | A1 |
20040098091 | Erbel et al. | May 2004 | A1 |
20040106972 | Deaton | Jun 2004 | A1 |
20040106978 | Greenberg et al. | Jun 2004 | A1 |
20040117003 | Ouriel et al. | Jun 2004 | A1 |
20040133266 | Clerc et al. | Jul 2004 | A1 |
20040162606 | Thompson | Aug 2004 | A1 |
20040171978 | Shalaby | Sep 2004 | A1 |
20040176832 | Hartley et al. | Sep 2004 | A1 |
20040181149 | Langlotz et al. | Sep 2004 | A1 |
20040215320 | MacHek | Oct 2004 | A1 |
20040215327 | Doig et al. | Oct 2004 | A1 |
20050010246 | Streeter et al. | Jan 2005 | A1 |
20050033406 | Barnhart et al. | Feb 2005 | A1 |
20050049678 | Cocks et al. | Mar 2005 | A1 |
20050065545 | Wallace | Mar 2005 | A1 |
20050070995 | Zilla et al. | Mar 2005 | A1 |
20050085900 | Case et al. | Apr 2005 | A1 |
20050102018 | Carpenter et al. | May 2005 | A1 |
20050102021 | Osborne | May 2005 | A1 |
20050131512 | Vonderwalde | Jun 2005 | A1 |
20050131517 | Hartley et al. | Jun 2005 | A1 |
20050143802 | Soykan | Jun 2005 | A1 |
20050149166 | Schaeffer et al. | Jul 2005 | A1 |
20050154448 | Cully et al. | Jul 2005 | A1 |
20050171598 | Schaeffer | Aug 2005 | A1 |
20050203606 | VanCamp | Sep 2005 | A1 |
20050222649 | Capuano | Oct 2005 | A1 |
20050222667 | Hunt | Oct 2005 | A1 |
20050222668 | Schaeffer et al. | Oct 2005 | A1 |
20050222669 | Purdy | Oct 2005 | A1 |
20050266042 | Tseng | Dec 2005 | A1 |
20050283188 | Loshakove et al. | Dec 2005 | A1 |
20060015170 | Jones et al. | Jan 2006 | A1 |
20060030911 | Letort | Feb 2006 | A1 |
20060052799 | Middleman et al. | Mar 2006 | A1 |
20060069426 | Weinberger | Mar 2006 | A1 |
20060095104 | Magers | May 2006 | A1 |
20060100684 | Elliott | May 2006 | A1 |
20060106406 | Weinberger | May 2006 | A1 |
20060149360 | Schwammenthal | Jul 2006 | A1 |
20060155358 | LaDuca et al. | Jul 2006 | A1 |
20060155366 | LaDuca et al. | Jul 2006 | A1 |
20060167476 | Burdulis, Jr. et al. | Jul 2006 | A1 |
20060173530 | Das | Aug 2006 | A1 |
20060190070 | Dieck et al. | Aug 2006 | A1 |
20060193892 | Furst et al. | Aug 2006 | A1 |
20060212113 | Shaolian et al. | Sep 2006 | A1 |
20060229709 | Morris et al. | Oct 2006 | A1 |
20060241740 | Vardi et al. | Oct 2006 | A1 |
20060281966 | Peacock, III | Dec 2006 | A1 |
20070016281 | Melsheimer | Jan 2007 | A1 |
20070021822 | Boatman | Jan 2007 | A1 |
20070027526 | Demetriades et al. | Feb 2007 | A1 |
20070043425 | Hartley et al. | Feb 2007 | A1 |
20070050011 | Klein et al. | Mar 2007 | A1 |
20070055326 | Farley et al. | Mar 2007 | A1 |
20070055350 | Erickson et al. | Mar 2007 | A1 |
20070055358 | Krolik et al. | Mar 2007 | A1 |
20070060989 | Deem et al. | Mar 2007 | A1 |
20070061002 | Paul, Jr. et al. | Mar 2007 | A1 |
20070073373 | Bonsignore | Mar 2007 | A1 |
20070088425 | Schaeffer | Apr 2007 | A1 |
20070112344 | Keilman | May 2007 | A1 |
20070135677 | Miller et al. | Jun 2007 | A1 |
20070142896 | Anderson et al. | Jun 2007 | A1 |
20070150051 | Menardiere et al. | Jun 2007 | A1 |
20070156167 | Connors et al. | Jul 2007 | A1 |
20070167898 | Peters et al. | Jul 2007 | A1 |
20070167955 | Menardiere et al. | Jul 2007 | A1 |
20070168018 | Amplatz et al. | Jul 2007 | A1 |
20070179598 | Duerig | Aug 2007 | A1 |
20070185565 | Schwammenthal et al. | Aug 2007 | A1 |
20070207186 | Scanlon et al. | Sep 2007 | A1 |
20070208410 | Berra et al. | Sep 2007 | A1 |
20070213805 | Schaeffer et al. | Sep 2007 | A1 |
20070213807 | Roubin et al. | Sep 2007 | A1 |
20070219610 | Israel | Sep 2007 | A1 |
20070219627 | Chu | Sep 2007 | A1 |
20070233229 | Berra et al. | Oct 2007 | A1 |
20070237973 | Purdy et al. | Oct 2007 | A1 |
20070239256 | Weber | Oct 2007 | A1 |
20070244542 | Greenan et al. | Oct 2007 | A1 |
20070244543 | Mitchell | Oct 2007 | A1 |
20070244547 | Greenan | Oct 2007 | A1 |
20070250154 | Greenberg et al. | Oct 2007 | A1 |
20070255388 | Rudakov et al. | Nov 2007 | A1 |
20080002871 | Gunzert-Marx et al. | Jan 2008 | A1 |
20080015673 | Chuter | Jan 2008 | A1 |
20080033527 | Nunez | Feb 2008 | A1 |
20080058918 | Watson | Mar 2008 | A1 |
20080064957 | Spence | Mar 2008 | A1 |
20080086193 | Thramann | Apr 2008 | A1 |
20080097578 | Erickson et al. | Apr 2008 | A1 |
20080109066 | Quinn | May 2008 | A1 |
20080114444 | Yu | May 2008 | A1 |
20080114445 | Melsheimer et al. | May 2008 | A1 |
20080140178 | Rasmussen | Jun 2008 | A1 |
20080147173 | McIff et al. | Jun 2008 | A1 |
20080167704 | Wright et al. | Jul 2008 | A1 |
20080176271 | Silver | Jul 2008 | A1 |
20080195190 | Bland et al. | Aug 2008 | A1 |
20080195191 | Luo et al. | Aug 2008 | A1 |
20080215134 | Lawrence-Brown | Sep 2008 | A1 |
20080249598 | Sherry | Oct 2008 | A1 |
20080262595 | Chu et al. | Oct 2008 | A1 |
20080269789 | Eli | Oct 2008 | A1 |
20080275540 | Wen | Nov 2008 | A1 |
20080275542 | LaDuca et al. | Nov 2008 | A1 |
20080288044 | Osborne | Nov 2008 | A1 |
20080300665 | Lootz et al. | Dec 2008 | A1 |
20080312732 | Hartley et al. | Dec 2008 | A1 |
20080319528 | Yribarren et al. | Dec 2008 | A1 |
20090012597 | Doig et al. | Jan 2009 | A1 |
20090012602 | Quadri | Jan 2009 | A1 |
20090030497 | Metcalf et al. | Jan 2009 | A1 |
20090030502 | Sun et al. | Jan 2009 | A1 |
20090048663 | Greenberg | Feb 2009 | A1 |
20090054967 | Das | Feb 2009 | A1 |
20090062899 | Dang et al. | Mar 2009 | A1 |
20090069882 | Venturelli et al. | Mar 2009 | A1 |
20090082841 | Zacharias et al. | Mar 2009 | A1 |
20090099640 | Weng | Apr 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090099648 | Yu | Apr 2009 | A1 |
20090099649 | Chobotov et al. | Apr 2009 | A1 |
20090099650 | Bolduc et al. | Apr 2009 | A1 |
20090105809 | Lee et al. | Apr 2009 | A1 |
20090112233 | Xiao | Apr 2009 | A1 |
20090125096 | Chu et al. | May 2009 | A1 |
20090138067 | Pinchuk et al. | May 2009 | A1 |
20090149877 | Hanson et al. | Jun 2009 | A1 |
20090227997 | Wang et al. | Sep 2009 | A1 |
20090240316 | Bruszewski | Sep 2009 | A1 |
20090248134 | Dierking et al. | Oct 2009 | A1 |
20090254170 | Hartley et al. | Oct 2009 | A1 |
20090259290 | Bruszewski et al. | Oct 2009 | A1 |
20090287145 | Cragg et al. | Nov 2009 | A1 |
20100004728 | Rao et al. | Jan 2010 | A1 |
20100029608 | Finley et al. | Feb 2010 | A1 |
20100063575 | Shalev | Mar 2010 | A1 |
20100070019 | Shalev | Mar 2010 | A1 |
20100082091 | Berez et al. | Apr 2010 | A1 |
20100161025 | Kuppurathanam et al. | Jun 2010 | A1 |
20100161026 | Brocker et al. | Jun 2010 | A1 |
20100168838 | Hartley et al. | Jul 2010 | A1 |
20100211159 | Schmid et al. | Aug 2010 | A1 |
20100256725 | Rasmussen | Oct 2010 | A1 |
20100274187 | Argentine | Oct 2010 | A1 |
20100274345 | Rust | Oct 2010 | A1 |
20100292774 | Shalev | Nov 2010 | A1 |
20100318171 | Porter et al. | Dec 2010 | A1 |
20100318180 | Porter | Dec 2010 | A1 |
20110022149 | Cox | Jan 2011 | A1 |
20110022153 | Schreck et al. | Jan 2011 | A1 |
20110040366 | Goetz et al. | Feb 2011 | A1 |
20110093002 | Rucker et al. | Apr 2011 | A1 |
20110125251 | Cottone et al. | May 2011 | A1 |
20110208289 | Shalev | Aug 2011 | A1 |
20110208296 | Duffy et al. | Aug 2011 | A1 |
20110208297 | Tuval | Aug 2011 | A1 |
20110208298 | Tuval | Aug 2011 | A1 |
20110218607 | Arbefeuille et al. | Sep 2011 | A1 |
20110218609 | Chobotov et al. | Sep 2011 | A1 |
20110218617 | Nguyen et al. | Sep 2011 | A1 |
20110257725 | Argentine | Oct 2011 | A1 |
20110262684 | Wintsch | Oct 2011 | A1 |
20110264184 | Heltai | Oct 2011 | A1 |
20110288622 | Chan et al. | Nov 2011 | A1 |
20120143317 | Cam | Jun 2012 | A1 |
20120158038 | Leschinsky | Jun 2012 | A1 |
20130116773 | Roeder et al. | May 2013 | A1 |
20130158646 | Roeder | Jun 2013 | A1 |
20130274866 | Cox | Oct 2013 | A1 |
20130338753 | Geusen | Dec 2013 | A1 |
20140316510 | Berra | Oct 2014 | A1 |
20140364930 | Strauss | Dec 2014 | A1 |
Number | Date | Country |
---|---|---|
2 497 704 | Mar 2004 | CA |
101045022 | Oct 2007 | CN |
201058061 | May 2008 | CN |
101980670 | Feb 2011 | CN |
101998845 | Mar 2011 | CN |
0893108 | Jan 1999 | EP |
1 177 779 | Feb 2002 | EP |
1177780 | Feb 2002 | EP |
1325716 | Jul 2003 | EP |
2 266 509 | Dec 2010 | EP |
2298248 | Mar 2011 | EP |
2000-279533 | Oct 2000 | JP |
2002-253682 | Sep 2002 | JP |
9639104 | Dec 1996 | WO |
9925273 | May 1999 | WO |
9951165 | Oct 1999 | WO |
02083038 | Oct 2002 | WO |
03034948 | May 2003 | WO |
2004017868 | Mar 2004 | WO |
2005002466 | Jan 2005 | WO |
2005037138 | Apr 2005 | WO |
2005041781 | May 2005 | WO |
2005041783 | May 2005 | WO |
2005046524 | May 2005 | WO |
2006007389 | Jan 2006 | WO |
2006028925 | Mar 2006 | WO |
2006070372 | Jul 2006 | WO |
2006088905 | Aug 2006 | WO |
2006130755 | Dec 2006 | WO |
2007084547 | Jul 2007 | WO |
2007115017 | Oct 2007 | WO |
2007144782 | Dec 2007 | WO |
2008008291 | Jan 2008 | WO |
2008021557 | Feb 2008 | WO |
2008035337 | Mar 2008 | WO |
2008042266 | Apr 2008 | WO |
2008047092 | Apr 2008 | WO |
2008047354 | Apr 2008 | WO |
2008051704 | May 2008 | WO |
2008053469 | May 2008 | WO |
2008066923 | Jun 2008 | WO |
2008107885 | Sep 2008 | WO |
2008140796 | Nov 2008 | WO |
2009078010 | Jun 2009 | WO |
2009116041 | Sep 2009 | WO |
2009116042 | Sep 2009 | WO |
2009118733 | Oct 2009 | WO |
2010024869 | Mar 2010 | WO |
2010024879 | Mar 2010 | WO |
2010031060 | Mar 2010 | WO |
2010042210 | Apr 2010 | WO |
2010045238 | Apr 2010 | WO |
2010062355 | Jun 2010 | WO |
2010088776 | Aug 2010 | WO |
2010128162 | Nov 2010 | WO |
2010150208 | Dec 2010 | WO |
2011004374 | Jan 2011 | WO |
2011007354 | Jan 2011 | WO |
2011055364 | May 2011 | WO |
2011064782 | Jun 2011 | WO |
2011067764 | Jun 2011 | WO |
2011070576 | Jun 2011 | WO |
2011080738 | Jul 2011 | WO |
2011095979 | Aug 2011 | WO |
2011106532 | Sep 2011 | WO |
2011106533 | Sep 2011 | WO |
2011106544 | Sep 2011 | WO |
2011136930 | Nov 2011 | WO |
2012049679 | Apr 2012 | WO |
2012104842 | Aug 2012 | WO |
2012111006 | Aug 2012 | WO |
2012117395 | Sep 2012 | WO |
Entry |
---|
“E-vita® open plus” product brochure (JOTEC GmbH, Hechingen, Germany) (2010). |
An English Translation of an Office Action dated Aug. 25, 2011, which issued during the prosecution of Chinese Patent Application No. 200880014919.9. |
Fonseca A et al., “Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions,” J Invasive Cardiol 20(1):21-7 (Jan. 2008). |
An International Search Report and a Written Opinion both dated Sep. 24, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000060. |
Khlif H et al., “Contribution to the Improvement of Textile Vascular Prostheses Crimping,” Trends in Applied Sciences Research 6(9):1019-1027 (2011). |
An International Search Report and a Written Opinion both dated Jul. 13, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000083. |
An International Search Report and a Written Opinion both dated Jul. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000095. |
An International Search Report and a Written Opinion both dated Aug. 31, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000148. |
An International Search Report and a Written Opinion both dated Sep. 6, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000190. |
An International Search Report and a Written Opinion both dated Jun. 19, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000241. |
An International Search Report and a Written Opinion both dated Nov. 27, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000300. |
An International Search Report and a Written Opinion both dated Feb. 4, 2011, which issued during the prosecution of Applicant's PCT/IB2010/052861. |
An International Search Report and a Written Opinion both dated Sep. 29, 2008, which issued during the prosecution of Applicant's PCT/IL08/000287. |
An International Search Report and a Written Opinion both dated Mar. 11, 2009, which issued during the prosecution of Applicant's PCT/IL2007/001312. |
An International Search Report and a Written Opinion both dated Jun. 30, 2009, which issued during the prosecution of Applicant's PCT/IL2008/001621. |
An International Search Report and a Written Opinion both dated Nov. 5, 2010, which issued during the prosecution of Applicant's PCTIL2010000549. |
An International Search Report and a Written Opinion both dated Dec. 3, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000564. |
An International Search Report and a Written Opinion both dated Mar. 10, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000917. |
An International Search Report and a Written Opinion both dated Aug. 4, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000999. |
An International Search Report and a Written Opinion both dated Mar. 30, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001018. |
An International Search Report and a Written Opinion both dated Apr. 18, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001037. |
An International Search Report and a Written Opinion both dated May 23, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001087. |
An International Search Report and a Written Opinion both dated Jun. 28, 2011, which issued during the prosecution of Applicant's PCT/IL2011/000135. |
An International Search Report dated Oct. 4, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000269. |
An Office Action dated Apr. 27, 2011, which issued during the prosecution of U.S. Appl. No. 12/447,684. |
An Office Action dated Nov. 12, 2010, which issued during the prosecution of U.S. Appl. No. 12/447,684. |
An Office Action dated Mar. 24, 2011, which issued during the prosecution of U.S. Appl. No. 12/529,936. |
An Office Action dated Oct. 28, 2011, which issued during the prosecution of U.S. Appl. No. 12/529,936. |
An Office Action dated Jun. 19, 2012, which issued during the prosecution of U.S. Appl. No. 12/808,037. |
An Office Action dated Oct. 11, 2012, which issued during the prosecution of U.S. Appl. No. 13/031,871. |
Ryhänen J., in “Biocompatibility evaluation of nickel-titanium shape memory metal alloy,” Academic Dissertation, Faculty of Medicine, Department of Surgery, University of Oulu, Finland (May 1999). |
International Search Report and Written Opinion dated Jun. 14, 2013 issued in PCT/IL2012/050506. |
EP Search in Appl. No. 12855964.8, dated Jun. 12, 2014. |
Non-final office action in U.S. Appl. No. 14/240,600, dated Jul. 30, 2014. |
Non-final office action in U.S. Appl. No. 13/513,397, dated Aug. 12, 2015. |
Final office action in U.S. Appl. No. 13/384,075, dated Sep. 23, 2015. |
Non-final OA in U.S. Appl. No. 13/577,161, dated Oct. 2, 2015. |
An International Search Report and Written Opinion issued on Nov. 26, 2013 in PCT/IL2013/050656. |
A non-final Office Action issued on Feb. 28, 2014 in U.S. Appl. No. 13/512,778. |
An International Search Report and a Written Opinion both dated Mar. 18, 2015, which issued during the prosecution of Applicant's PCT/IL2014/050973. |
European Search Report for European Patent Application No. 12741804.4 dated Jun. 30, 2014. |
Communication dated Sep. 4, 2014, from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/519,971. |
An Office Action dated Dec. 9, 2015, which issued during the prosecution of U.S. Appl. No. 14/416,236. |
European Search Report dated Jan. 18, 2016 which issued during the prosecution of Applicant's European App No. 10799521.9. |
An Office Action dated Feb. 1, 2016, which issued during the prosecution of U.S. Appl. No. 14/241,793. |
An International Search Report and a Written Opinion both dated Feb. 17, 2016, which issued during the prosecution of Applicant's PCT/IL2015/051221. |
An Office Action dated Feb. 23, 2016, which issued during the prosecution of U.S. Appl. No. 14/416,236. |
An Office Action dated Mar. 7, 2016, which issued during the prosecution of U.S. Appl. No. 14/240,600. |
European Search Report dated Mar. 11, 2016 which issued during the prosecution of Applicant's European App No. 11739497.3. |
An Invitation to pay additional fees dated Apr. 12, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050014. |
European Search Report dated Mar. 15, 2016 which issued during the prosecution of Applicant's European App No. 13825456.0. |
An Office Action dated Mar. 28, 2016, which issued during the prosecution of U.S. Appl. No. 14/362,194. |
Scurr et al., “Fenestrated Aortic Stent Grafts,” Semin Intervent Radiol. Jun. 2007; 24(2): 211-220. |
An Office Action dated Apr. 14, 2016, which issued during the prosecution of Canadian Patent Application No. 2,766,347. |
European Search Report dated May 23, 2016 which issued during the prosecution of Applicant's European App No. 10832752.9. |
An International Search Report and a Written Opinion both dated Jun. 21, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050014. |
An Office Action dated Jul. 22, 2016, which issued during the prosecution of Chinese Patent Application No. 201480012648.9. |
An Office Action dated Aug. 3, 2016, which issued during the prosecution of U.S. Appl. No. 14/241,793. |
Number | Date | Country | |
---|---|---|---|
20130131783 A1 | May 2013 | US |
Number | Date | Country | |
---|---|---|---|
61438977 | Feb 2011 | US |